2025 Formulary Changes



These changes will be effective 1/1/25 for Commercial and Exchange plans.

Medication	Change
Oxbryta	Removing from formulary due to product being discontinued by the manufacturer (new safety data indicates risks of therapy do not outweigh the benefits)
Relyvrio	Removing from formulary due to product being discontinued by the manufacturer (lack of established clinical efficacy)
Tegsedi	Removing from formulary due to product being discontinued by the manufacturer (steady decline in market usage)
Victoza	Moving from Preferred Brand to Non-Preferred Brand tier

These changes will be effective 2/1/25 for Commercial and Exchange plans.

Medication	Change
Compounding Kits and Wound Dressings	Removing from formulary because there are over-the-counter alternatives available

These changes will be effective 4/1/25 for Commercial and Exchange plans.

Medication	Change
BRAND Sprycel	Removing BRAND from formulary since the generic for this drug, dasatinib, is covered
BRAND Stelara products	Removing BRAND Stelara products from formulary because ustekinumab biosimilars will be added when available
diclofenac 25mg immediate release products	Removing from formulary due to the availability of delayed release formulations and immediate release formulations in other strengths